2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2599

The Effect of Daily Low Dose Prednisone (divided daily versus single daily dose) in the Treatment of African Americans (AA) with Early Rheumatoid Arthritis (RA)
Abstract Number: 2600

Signs of Immune Activation and Local Inflammation Are Present in the Bronchial Tissue of Patients with Untreated Early Rheumatoid Arthritis
Abstract Number: 2601

The Multi-Biomarker Disease Activity Score in a TNF Inhibitor Tapering Study in Rheumatoid Arthritis Patients: Predictive Value for Successful Tapering, Flaring and Radiographic Progression
Abstract Number: 2602

CCP Antibody Negativity Is Associated with Higher Fatigue in Rheumatoid Arthritis
Abstract Number: 2603

What Is the Variability of HAQ over Time in Patients with Rheumatoid Arthritis Treated with Anti-TNF?
Abstract Number: 2604

Evaluation of Serum Undercarboxylated Osteocalcin in Premenopausal Rheumatoid Arthritis Patients; Its Correlation with Disease Activity and Bone Mineral Density
Abstract Number: 2605

14-3-3η Positive Status and Higher Titres Are Associated with More Severe RA
Abstract Number: 2606

Serum Myeloid Related Protein 8/14 Levels in Rheumatoid Arthritis: Marker of Disease Activity and Response to Methotrexate in DMARD Naïve Patients
Abstract Number: 2607

Anti-Cyclic Citrullinated Peptide Antibodies and Rheumatoid Factor in Rheumatoid Arthritis Hispanics Exposed to Biomass Smoke
Abstract Number: 2608

The “Rheumatoid Arthritis Impact of Disease”� Score Correlates with Other Patient Reported Outcomes and with Disease Activity Scores in Patients with RA and Its Patient Acceptable Symptom State Is More Stringent Than DAS28-Remission
Abstract Number: 2609

The Measurement of the Skin Autofluorescence As an Indicator of Disease Progression in Rheumatoid Arthritis Patients
Abstract Number: 2610

Real-World Use of Tocilizumab in Rheumatoid Arthritis Patients: Cardiovascular Risk, Concomitant Treatment, and Outcomes over 6 Months of Follow-up
Abstract Number: 2611

Circulating Monocyte Count Is Significantly Associated with Interstitial Pneumonia in Biologic-Naive Patients with Rheumatoid Arthritis: A Single-Center Prospective Cohort Study (Keio First-Bio Cohort Study)
Abstract Number: 2612

Impact of a Multibiomarker Disease Activity Score in Patients with Rheumatoid Arthritis Treated in a Real World Setting
Abstract Number: 2613

Patient Reported Physical Capacity Correlates with Phenylalanine Serum Levels in Patients with Early Untreated Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].